{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:55:24Z","timestamp":1790283324800,"version":"4.1.0"},"reference-count":38,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Victor Babes University of Medicine and Pharmacy, Timisoara, Romania\n\t\t\t\t\t\t\t\t\t\t\t\t\t              https:\/\/ror.org\/00afdp487"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Psoriatic disease is a systemic inflammatory condition associated with increased cardiometabolic risk, but the impact of contemporary systemic therapies and narrowband ultraviolet B (NB-UVB) phototherapy on vascular and systemic inflammatory markers remains incompletely characterized. We aimed to systematically synthesize prospective evidence on treatment-associated changes in vascular inflammation and systemic inflammatory biomarkers in adults with moderate-to-severe psoriatic disease. Specifically, we evaluated changes assessed by 18F-FDG PET\/CT imaging and circulating biomarkers following biologic therapies or NB-UVB phototherapy. Methods: We systematically searched MEDLINE, Embase, Web of Science, Scopus, and CENTRAL from inception to 31 January 2026 for prospective interventional and observational studies in adults with psoriasis or psoriatic arthritis treated with biologic agents targeting TNF-\u03b1, IL-12\/23, IL-17, or IL-23, or with NB-UVB phototherapy. Eligible studies were required to report serial assessments of vascular inflammation by 18F-FDG PET\/CT (typically aortic target-to-background ratio) and\/or systemic inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, TNF-\u03b1, GlycA, or hematologic indices such as the neutrophil-to-lymphocyte ratio) over at least 8 weeks of follow-up. We imposed no language restrictions and included only full-text, peer-reviewed prospective studies. Risk of bias was evaluated using RoB 2 for randomized trials and ROBINS-I for nonrandomized studies. Random-effects meta-analyses were prespecified for outcomes reported by at least two clinically comparable studies; however, because of substantial heterogeneity in reporting and methodology, effect estimates were summarized using a structured narrative synthesis. Results: Thirteen prospective studies (n \u2248 900 adults, published 2015\u20132025) met inclusion criteria, including four studies with serial 18F-FDG PET\/CT imaging and one additional PET\/CT study providing baseline observational data on vascular inflammation, as well as eight biomarker-focused prospective cohorts. Across randomized mechanistic trials and observational studies, biologic therapies reduced aortic target-to-background ratio by approximately 6\u201312% over 12\u201324 weeks (e.g., mean change from 2.42 to 2.18 with TNF-\u03b1 inhibition and from 2.51 to 2.20 with IL-17 blockade), and no study reported worsening of PET-derived vascular indices under effective systemic treatment. Biologic and other systemic therapies produced concordant reductions in hs-CRP (typically by 30\u201350%), IL-6, TNF-\u03b1, GlycA, and blood-count-derived indices including neutrophil-to-lymphocyte ratio, with biomarker improvements frequently paralleling reductions in cutaneous disease activity and cardiometabolic risk markers. Two NB-UVB cohorts demonstrated significant hs-CRP reductions of roughly 20\u201330% and modulation of vitamin D-related inflammatory proteins, suggesting systemic anti-inflammatory effects, although these changes appeared less pronounced than with biologic therapy and were not accompanied by vascular imaging. Conclusions: Contemporary systemic psoriasis therapies, particularly biologic agents targeting the IL-23\/Th17 axis and TNF-\u03b1, are associated with consistent reductions in aortic vascular inflammation and broad improvements in systemic inflammatory biomarkers, whereas NB-UVB phototherapy confers more modest but measurable systemic anti-inflammatory effects, although the current evidence does not allow differentiation between individual biologic classes in terms of magnitude of effect. Although reductions in vascular and systemic inflammatory markers were observed across therapies targeting TNF-\u03b1, IL-12\/23, IL-17, and IL-23, the small number of mechanistic imaging studies and absence of head-to-head comparisons do not allow robust differentiation between biologic classes or support a uniform class effect. The convergence of imaging and biomarker data reinforces psoriasis as a clinically relevant model of inflammation-driven atherosclerosis and supports the concept that effective control of psoriatic inflammation may contribute to cardiovascular risk modification, highlighting the need for integrated cardiovascular risk assessment in routine care. However, the imaging evidence base remains limited to four small mechanistic PET\/CT studies with relatively short follow-up, which constrains the strength and generalizability of conclusions regarding vascular inflammation. Larger, adequately powered, event-driven prospective trials with standardized imaging and biomarker endpoints are needed to determine whether these vascular and systemic anti-inflammatory effects translate into reduced cardiovascular events in psoriatic disease; because of methodological and reporting heterogeneity across the 13 included studies, these conclusions are based on a structured narrative synthesis rather than a formal quantitative meta-analysis. PROSPERO registration number: CRD420261296646.<\/jats:p>","DOI":"10.3390\/jcm15072589","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:22:36Z","timestamp":1774858956000},"page":"2589","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of Biologic Therapies and Narrowband UVB Phototherapy on Vascular Inflammation and Systemic Inflammatory Biomarkers in Psoriasis: A Systematic Review and Narrative Synthesis of Prospective Studies"],"prefix":"10.3390","volume":"15","author":[{"given":"Ana-Olivia","family":"Toma","sequence":"first","affiliation":[{"name":"Department of Dermatology, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Center for the Morphologic Study of the Skin (MORPHODERM), \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Crainic","sequence":"additional","affiliation":[{"name":"Center for the Morphologic Study of the Skin (MORPHODERM), \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"},{"name":"Doctoral School, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4951-1702","authenticated-orcid":false,"given":"Diana-Maria","family":"Mateescu","sequence":"additional","affiliation":[{"name":"Doctoral School, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0776-0809","authenticated-orcid":false,"given":"Roxana Manuela","family":"Fericean","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Center for the Morphologic Study of the Skin (MORPHODERM), \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9681-8289","authenticated-orcid":false,"given":"Nicolae Ciprian","family":"Pilut","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Center for the Morphologic Study of the Skin (MORPHODERM), \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2187-289X","authenticated-orcid":false,"given":"Nina","family":"Ivanovic","sequence":"additional","affiliation":[{"name":"Center for the Morphologic Study of the Skin (MORPHODERM), \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"},{"name":"Doctoral School, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8837-1558","authenticated-orcid":false,"given":"Daniela Vasilica","family":"Serban","sequence":"additional","affiliation":[{"name":"Center for the Morphologic Study of the Skin (MORPHODERM), \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"},{"name":"Doctoral School, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s13555-025-01566-0","article-title":"Cardiovascular disease and psoriasis","volume":"16","author":"Ponikowska","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.jacc.2021.02.009","article-title":"Cardiovascular risk in patients with psoriasis: JACC review topic of the week","volume":"77","author":"Garshick","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Hsu, L.N., and Lan, C.-C.E. (2017). Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18102211"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD\u2013NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamadermatol.2024.4433","article-title":"Skin inflammation, systemic inflammation, and cardiovascular disease in psoriasis","volume":"161","author":"Svedbom","year":"2025","journal-title":"JAMA Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yao, Y., Chen, L.-Q., Lv, Y.-B., Tang, S.-L., Shen, W., Sun, H., and Zhong, H.-J. (2025). Skin immune microenvironment in psoriasis: From bench to bedside. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1643418"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jacc.2013.04.066","article-title":"Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: Results of a multicenter fluorodeoxyglucose-positron emission tomography\/computed tomography feasibility study","volume":"62","author":"Tawakol","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jcmg.2013.08.006","article-title":"Measurement of arterial activity on routine FDG PET\/CT images improves prediction of risk of future cardiovascular events","volume":"6","author":"Figueroa","year":"2013","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12967-017-1321-6","article-title":"GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk","volume":"15","author":"Connelly","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1755-7682-5-2","article-title":"Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population","volume":"5","author":"Imtiaz","year":"2012","journal-title":"Int. Arch. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/archdermatol.2012.2502","article-title":"Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis","volume":"148","author":"Wu","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e000062","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major adverse cardiovascular events: A systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1365-2133.2012.10883.x","article-title":"Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis","volume":"166","author":"Carrascosa","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Sch\u00f6n, M.P., and Erpenbeck, L. (2018). The interleukin-23\/interleukin-17 axis links adaptive and innate immunity in psoriasis pathogenesis. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01323"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e007394","DOI":"10.1161\/CIRCIMAGING.117.007394","article-title":"Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: A randomized placebo-controlled trial","volume":"11","author":"Mehta","year":"2018","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","article-title":"A randomized placebo-controlled trial of ustekinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-U)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jid.2020.01.025","article-title":"A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1161\/CIRCRESAHA.116.309637","article-title":"GlycA is a novel biomarker of inflammation and subclinical cardiovascular disease in psoriasis","volume":"119","author":"Joshi","year":"2016","journal-title":"Circ. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1007\/s12350-023-03204-8","article-title":"Anti-inflammatory effect of biologic therapy in patients with psoriatic disease: A prospective cohort FDG PET study","volume":"30","author":"Boczar","year":"2023","journal-title":"J. Nucl. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e12725","DOI":"10.1111\/sji.12725","article-title":"Serum cytokine measurements and biological therapy of psoriasis\u2014Prospects for personalized treatment?","volume":"88","author":"Solberg","year":"2018","journal-title":"Scand. J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"601","DOI":"10.5021\/ad.2019.31.6.601","article-title":"The effects of systemic psoriasis therapies on the C-reactive protein and the neutrophil-lymphocyte ratio","volume":"31","author":"Karabay","year":"2019","journal-title":"Ann. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1590\/abd1806-4841.20164655","article-title":"C-reactive protein serum level in patients with psoriasis before and after treatment with narrow-band ultraviolet B","volume":"91","author":"Farshchian","year":"2016","journal-title":"An. Bras. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Elmelid, A., Vandikas, M.S., Gillstedt, M., Alsterholm, M., and Osmancevic, A. (2024). The effect of phototherapy on systemic inflammation measured with serum vitamin D-binding protein and hsCRP in patients with inflammatory skin disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25168632"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Morariu, S.-H., Cotoi, O.S., Tiuc\u0103, O.M., Baican, A., Gheuc\u0103-Solov\u0103stru, L., Decean, H., Brihan, I., Silaghi, K., Biro, V., and \u0218erban-Pescar, D. (2024). Blood-count-derived inflammatory markers as predictors of response to biologics and small-molecule inhibitors in psoriasis: A multicenter study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13143992"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Matei-Man, A.-M., Vesa, \u0218.C., Pu\u0219ca\u0219, A.D., Or\u0103san, M.S., Homorozeanu, B., Candrea, E., and Mocan, T. (2025). Assessment of TNF-\u03b1, IL-12\/23, and IL-17 in psoriasis: Only TNF-\u03b1 reflects clinical response after 12 weeks of biologic treatment. Curr. Issues Mol. Biol., 47.","DOI":"10.3390\/cimb47050368"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"15528","DOI":"10.1038\/s41598-025-99075-9","article-title":"Cutaneous and systemic improvements in psoriasis patients after different biologic treatments in a real-world longitudinal prospective study","volume":"15","author":"Ntawuyamara","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1161\/ATVBAHA.115.306460","article-title":"Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET\/CT and neutrophil activation in a prospective observational study","volume":"35","author":"Naik","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Libby, P. (2021). Targeting inflammatory pathways in cardiovascular disease: The inflammasome, interleukin-1, interleukin-6 and beyond. Cells, 10.","DOI":"10.3390\/cells10040951"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Lin, T.-L., Fan, Y.-H., Fan, K.-S., Juan, C.-K., Chen, Y.-J., and Wu, C.-Y. (2025). Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-\u03b1, IL-12\/23, IL-17, and IL-23: A population-based retrospective cohort study. PLoS Med., 22.","DOI":"10.1371\/journal.pmed.1004591"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors and other anti-inflammatory therapies on cardiovascular events in inflammatory diseases: A systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"107074","DOI":"10.1016\/j.phrs.2024.107074","article-title":"Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project","volume":"200","author":"Ingrasciotta","year":"2024","journal-title":"Pharmacol. Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2589\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T12:16:52Z","timestamp":1774873012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15072589"],"URL":"https:\/\/doi.org\/10.3390\/jcm15072589","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]}}}